Next Article in Journal
Comparison of Diagnostic Values of Maternal Arginine Concentration for Different Pregnancy Complications: A Systematic Review and Meta-Analysis
Next Article in Special Issue
Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer
Previous Article in Journal
Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 10
Issue 1
10.3390/biomedicines10010164
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes

by
Sandra Orrù
1,†,
Emanuele Pascariello
1,†,
Giovanni Sotgiu
2,
Daniela Piras
3,
Laura Saderi
2,
Maria Rosaria Muroni
2,
Ciriaco Carru
4,
Caterina Arru
4,
Cristina Mocci
1,
Giampietro Pinna
1,
Raffaele Barbara
5,
Paolo Cossu-Rocca
2,6 and
Maria Rosaria De Miglio
2,*
1
Department of Pathology, “A. Businco” Oncologic Hospital, ARNAS Brotzu, Via Edward Jenner 1, 09121 Cagliari, Italy
2
Department of Medical, Surgical and Experimental Sciences, University of Sassari, Via P. Manzella 4, 07100 Sassari, Italy
3
Struttura Complessa Epidemiologia e Registro Tumori Nord Sardegna, ATS Sardegna, Via Rizzeddu 2, 07100 Sassari, Italy
4
Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43, 07100 Sassari, Italy
5
Department of Radiotherapy, “A. Businco” Oncologic Hospital, ARNAS Brotzu, Via Edward Jenner 1, 09121 Cagliari, Italy
6
Department of Diagnostic Services, “Giovanni Paolo II” Hospital, ASSL Olbia-ATS Sardegna, Via Bazzoni—Sircana, 07026 Olbia, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomedicines 2022, 10(1), 164; https://doi.org/10.3390/biomedicines10010164
Submission received: 6 December 2021 / Revised: 3 January 2022 / Accepted: 11 January 2022 / Published: 13 January 2022
(This article belongs to the Special Issue Breast Cancer: From Biology to Therapeutic Opportunities)
Browse Figures
Review Reports Versions Notes

Abstract

HER2+ breast cancer (BC) is an aggressive subtype representing a genetically and biologically heterogeneous group of tumors resulting in variable prognosis and treatment response to HER2-targeted therapies according to estrogen (ER) and progesterone receptor (PR) expression. The relationship with androgen receptors (AR), a member of the steroid hormone’s family, is unwell known in BC. The present study aims to evaluate the prognostic impact of AR expression in HER2+ BC subtypes. A total of 695 BCs were selected and reviewed, AR, ER, PR and HER2 expression in tumor cells were examined by immunohistochemical method, and the SISH method was used in case of HER2 with equivocal immunohistochemical score (2+). A high prevalence of AR expression (91.5%) in BC HER+ was observed, with minimal differences between luminal and non-luminal tumor. According to steroid receptor expression, tumors were classified in four subgroups, including BC luminal and non-luminal HER2+ expressing or not AR. The luminal BC HER2 + AR+ was associated with lower histological grade, lower tumor size, higher PR expression and lower HER2 intensity of expression (2+). Also, the non-luminal tumors AR+ showed lower tumor size and lower prognostic stage but frequently higher grade and higher HER2 intensity of expression (3+). These findings should suggest a different progression of luminal and non-luminal tumors, both expressing AR, and allow us to speculate that the molecular mechanisms of AR, involved in the biology of BC HER2 + AR+, differ in relation to ER and PR expression. Moreover, AR expression may be a useful predictor of prognosis for overall survival (OS) in HER2+ BC subtypes. Our findings suggest that AR expression evaluation in clinical practice could be utilized in clinical oncology to establish different aggressiveness in BC HER2+ subtypes.
Keywords: HER2 expression; AR expression; breast cancer; prognosis; immunohistochemistry HER2 expression; AR expression; breast cancer; prognosis; immunohistochemistry

Share and Cite

MDPI and ACS Style

Orrù, S.; Pascariello, E.; Sotgiu, G.; Piras, D.; Saderi, L.; Muroni, M.R.; Carru, C.; Arru, C.; Mocci, C.; Pinna, G.; et al. Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes. Biomedicines 2022, 10, 164. https://doi.org/10.3390/biomedicines10010164

AMA Style

Orrù S, Pascariello E, Sotgiu G, Piras D, Saderi L, Muroni MR, Carru C, Arru C, Mocci C, Pinna G, et al. Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes. Biomedicines. 2022; 10(1):164. https://doi.org/10.3390/biomedicines10010164

Chicago/Turabian Style

Orrù, Sandra, Emanuele Pascariello, Giovanni Sotgiu, Daniela Piras, Laura Saderi, Maria Rosaria Muroni, Ciriaco Carru, Caterina Arru, Cristina Mocci, Giampietro Pinna, and et al. 2022. "Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes" Biomedicines 10, no. 1: 164. https://doi.org/10.3390/biomedicines10010164

APA Style

Orrù, S., Pascariello, E., Sotgiu, G., Piras, D., Saderi, L., Muroni, M. R., Carru, C., Arru, C., Mocci, C., Pinna, G., Barbara, R., Cossu-Rocca, P., & De Miglio, M. R. (2022). Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes. Biomedicines, 10(1), 164. https://doi.org/10.3390/biomedicines10010164

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop